@imakglobal : Merck is changing the way Keytruda is delivered, from an IV infusion to a subcutaneous injection, so it can thwart biosimilar competition and continue price gouging people with cancer. It's a tactic known as “product hopping" and it's a form of patent abuse. Here’s how it works. • TwiCopy

Initiative for Medicines, Access & Knowledge

@imakglobal

+ Follow

We are a team of lawyers, scientists, and health experts challenging systemic injustice and advocating for health equity in drug development and access.

ID: 3220653739

linkhttp://www.i-mak.org calendar_today19-05-2015 18:24:39

5,5K Tweet

9,9K Takipçi

986 Takip Edilen

Initiative for Medicines, Access & Knowledge

@imakglobal

3 months ago

Merck is changing the way Keytruda is delivered, from an IV infusion to a subcutaneous injection, so it can thwart biosimilar competition and continue price gouging people with cancer. It's a tactic known as “product hopping" and it's a form of patent abuse. Here’s how it works.

thumb_up_off_alt6

chat_bubble_outline1

repeat4

shareShare